Lista de obras -

Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.

artículo científico publicado en 2013

Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis ⬇️

artículo científico publicado el 1 de marzo de 2011

Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone

artículo científico publicado en 2019

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

artículo científico

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

artículo científico publicado en 2011

Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells.

artículo científico publicado en 2016

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes.

artículo científico publicado en 2018

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease

artículo científico publicado en 2015

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

artículo científico

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy

artículo científico publicado en 2002

High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients

scientific article published on 21 December 2007

Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss

artículo científico publicado en 2017

Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

artículo científico publicado en 2005

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

artículo científico publicado en 2017

Osteogenic differentiation of human mesenchymal stem cells in mineralized alginate matrices.

artículo científico publicado en 2015

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

artículo científico publicado en 2002

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.

artículo científico publicado en 2010

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2012

Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.

artículo científico publicado en 2009

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor

scientific article published on 18 July 2002

Serum protein N-glycosylation changes in multiple myeloma.

artículo científico publicado en 2019

Smac-mimetics reduce numbers and viability of human osteoclasts

artículo científico publicado en 2021

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

scientific article published on 01 January 2005

The Primary Function of gp130 Signaling in Osteoblasts Is To Maintain Bone Formation and Strength, Rather Than Promote Osteoclast Formation

article

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma

artículo científico publicado en 2015

gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation

artículo científico publicado en 2014

Lista de obras de

Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.

Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis ⬇️

Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells.

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes.

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy

High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients

Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss

Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Osteogenic differentiation of human mesenchymal stem cells in mineralized alginate matrices.

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib

Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor

Serum protein N-glycosylation changes in multiple myeloma.

Smac-mimetics reduce numbers and viability of human osteoclasts

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

The Primary Function of gp130 Signaling in Osteoblasts Is To Maintain Bone Formation and Strength, Rather Than Promote Osteoclast Formation

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma

gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation